



- [1] **“Eighth Edition Staging of Thoracic Malignancies: Implications for the Reporting Pathologist,”** *Arch. Pathol. Lab. Med.*, May 2018.
- [2] **“Prevention of Transfusion-Associated Graft-Versus-Host Disease With Blood Product Irradiation: The Past, Present, and Future,”** *Arch. Pathol. Lab. Med.*, May 2018.
- [3] **“Determining the Value of Cerebrospinal Fluid Lactate Dehydrogenase Level in Differentiating Subarachnoid Hemorrhage From Traumatic Lumbar Puncture,”** *Arch. Pathol. Lab. Med.*, May 2018.
- [4] **“Augmented Reality Technology Using Microsoft HoloLens in Anatomic Pathology,”** *Arch. Pathol. Lab. Med.*, May 2018.
- [5] **“Human Papillomavirus Testing in Head and Neck Carcinomas: Guideline From the College of American Pathologists,”** *Arch. Pathol. Lab. Med.*, May 2018.
- [6] **“Reproducibility and Feasibility of Strategies for Morphologic Assessment of Renal Biopsies Using the Nephrotic Syndrome Study Network Digital Pathology Scoring System,”** *Arch. Pathol. Lab. Med.*, May 2018.
- [7] **“Nipple-Invasive Primary Carcinomas: Clinical, Imaging, and Pathologic Features of Breast Carcinomas Originating in the Nipple,”** *Arch. Pathol. Lab. Med.*, May 2018.
- [8] **“Sensitive *NPM1* Mutation Quantitation in Acute Myeloid Leukemia Using Ultradeep Next-Generation Sequencing in the Diagnostic Laboratory,”** *Arch. Pathol. Lab. Med.*, May 2018.
- [9] **“Utility of Alternate, Noncentromeric Chromosome 17 Reference Probe for Human Epidermal Growth Factor Receptor Fluorescence In Situ Hybridization Testing in Breast Cancer Cases,”** *Arch. Pathol. Lab. Med.*, May 2018.
- [10] **“Focusing on Preinvasive Neoplasia,”** *Arch. Pathol. Lab. Med.*, May 2018.

## Seminars in Diagnostic Pathology

- [1] **“Diagnosis and management of metastatic neoplasms with unknown primary,”** *Semin. Diagn. Pathol.*, May 2018.
- [2] **“Hereditary SWI/SNF complex deficiency syndromes,”** *Semin. Diagn. Pathol.*, May 2018.
- [3] **“Morphological clues to the appropriate recognition of hereditary renal neoplasms,”** *Semin. Diagn. Pathol.*, May 2018.
- [4] **“Hereditary gastrointestinal carcinomas and their precursors: An algorithm for genetic testing,”** *Semin. Diagn. Pathol.*, May 2018.
- [5] **“Next generation immunohistochemistry: Emerging substitutes to genetic testing?,”** *Semin. Diagn. Pathol.*, May 2018.

- [6] **“Pathologists – The watchpersons for hereditary tumor syndromes,”** *Semin. Diagn. Pathol.*, May 2018.
- [7] **“Uncovering Hereditary Tumor Syndromes: Emerging Role of Surgical Pathology,”** *Semin. Diagn. Pathol.*, May 2018.



Version:1.0 StartHTML:0000000107 EndHTML:0000004261 StartFragment:0000000127  
EndFragment:0000004243

- [1] **“[Skin, a target for autoimmune, infectious and drug induced diseases],”** *Ann. Pathol.*, Feb. 2018.
- [2] **“[The key role of the pathologist in the diagnosis of syphilis: A case report],”** *Ann. Pathol.*, Feb. 2018.
- [3] **“[Humoral immune diseases: Cutaneous vasculitis and auto-immune bullous dermatoses],”** *Ann. Pathol.*, Feb. 2018.
- [4] **“[Histopathology of cutaneous drug reactions],”** *Ann. Pathol.*, Feb. 2018.
- [5] **“[Cutaneous infections: Pathologist’s role in unusual or atypical situations],”** *Ann. Pathol.*, Feb. 2018.
- [6] **“[Practices in infectious pathology in France in 2015. Results of the national survey],”** *Ann. Pathol.*, Feb. 2018.
- [7] **“[Cell-mediated immunity: Lupus and connective tissue diseases],”** *Ann. Pathol.*, Feb. 2018.
- [8] **“[A peculiar intra-uterine lesion: Inflammatory myofibroblastic tumor (IMT)],”** *Ann. Pathol.*, Apr. 2018.
- [9] **“[Endometrial carcinoma: An histopathological and histoprognostic study about 62 patients in a center in the Tunisian north],”** *Ann. Pathol.*, Apr. 2018.
- [10] **“[Ovarian Sertoli-Leydig tumor: A tricky tumor],”** *Ann. Pathol.*, Apr. 2018.
- [11] **“[A &quot;four-leaf clover&quot; case of colonic adenocarcinoma],”** *Ann. Pathol.*, Apr. 2018.
- [12] **“[Simple mucinous cyst of the pancreas: Case-report and literature review],”** *Ann. Pathol.*, Apr. 2018.
- [13] **“[PD-L1 testing in non-small cell lung carcinoma: Guidelines from the PATTERN group of thoracic pathologists],”** *Ann. Pathol.*, Apr. 2018.
- [14] **“[A Massive Open Oneline Course (MOOC) on practical histology: A goal, a tool, a large public ! Return on a first experience],”** *Ann. Pathol.*, Apr. 2018.
- [15] **“[Rich and sad topics],”** *Ann. Pathol.*, Apr. 2018.
- [16] **“[Chordoma cutis, an unusual clinical presentation of a rare neoplasm: Chordoma],”** *Ann. Pathol.*, Apr. 2018.

- [17] “[Benign and malignant giant-cell rich lesions of bone: Pathological diagnosis with special emphasis on recent immunohistochemistry and molecular techniques],” *Ann. Pathol.*, Apr. 2018.
- [18] “[Neuropathology of sudden infant death syndrome: Review of the literature and proposal of a protocol for neuropathological examination],” *Ann. Pathol.*, Apr. 2018.



- [1] “Insulinoma-associated protein 1 (INSM1) differentiates carcinoid tumourlets of the lung from pulmonary meningothelial-like nodules,” *Histopathology*, May 2018.
- [2] “Hepatic progenitor cells in metastatic liver carcinomas,” *Histopathology*, May 2018.
- [3] “Eosinophilic solid and cystic renal cell carcinomas have metastatic potential,” *Histopathology*, May 2018.
- [4] “Expression analysis of HMGB1 in histological samples of malignant pleural mesothelioma,” *Histopathology*, May 2018.
- [5] “Three-dimensional reconstruction of prostate cancer architecture with serial immunohistochemical sections: hallmarks of tumour growth, tumour compartmentalisation, and implications for grading and heterogeneity,” *Histopathology*, May 2018.
- [6] “Malignant mesothelioma *in situ*,” *Histopathology*, May 2018.
- [7] “Improved diagnostic stratification of digitised Barrett’s oesophagus biopsies by p53 immunohistochemical staining,” *Histopathology*, May 2018.
- [8] “Gastric pyloric gland adenoma: a multicentre clinicopathological study of 67 cases,” *Histopathology*, May 2018.
- [9] “Expression of PD-L1 correlates with pleomorphic morphology and histological patterns of non-small-cell lung carcinomas,” *Histopathology*, May 2018.
- [10] “Digital image analysis of Ki67 in hot spots is superior to both manual Ki67 and mitotic counts in breast cancer,” *Histopathology*, May 2018.
- [11] “Histological assessment of the liver explant in transplanted hepatitis C virus patients achieving sustained virological response with direct-acting antiviral agents,” *Histopathology*, May 2018.
- [12] “Invasive mucinous carcinoma of the breast and response patterns after neoadjuvant chemotherapy (NAC),” *Histopathology*, May 2018.
- [13] “Role of conventional immunomarkers, HNF4- $\alpha$  and SATB2, in the differential diagnosis of pulmonary and colorectal adenocarcinomas,” *Histopathology*, May 2018.
- [14] “Expression pattern of immunosurveillance-related antigen in adult T cell leukaemia/lymphoma,” *Histopathology*, May 2018.
- [15] “Aggressive natural killer (NK)-cell leukaemia and extranodal NK/T-cell lymphoma are two distinct diseases that differ in their clinical presentation and cytogenetic findings,” *Histopathology*, May 2018.

- [16] **“A decreased peritumoral CD1a+ cell number predicts a worse prognosis in oral squamous cell carcinoma,”** *Histopathology*, May 2018.
- [17] **“Primary effusion lymphoma in Taiwan shows two distinctive clinicopathological subtypes with rare human immunodeficiency virus association,”** *Histopathology*, May 2018.
- [18] **“Histopathology of synovial cysts of the spine,”** *Histopathology*, May 2018.
- [19] **“The World Health Organisation 2016 classification of penile carcinomas: a review and update from the International Society of Urological Pathology expert-driven recommendations,”** *Histopathology*, May 2018.
- [20] **“Giant cell tumours of bone treated with denosumab: histological, immunohistochemical and H3F3A mutation analyses,”** *Histopathology*, May 2018.



## Diagnostic Histopathology

- [1] **“Dermal chondroid syringoma,”** *Diagnostic Histopathol.*, May 2018.
- [2] **“Salivary gland neoplasms: diagnostic approach with focus on patterns of recognition and useful ancillary tools,”** *Diagnostic Histopathol.*, May 2018.
- [3] **“Oral potentially malignant disorders,”** *Diagnostic Histopathol.*, May 2018.
- [4] **“Evolving concepts and new entities in the 2017 WHO classification of salivary gland tumors,”** *Diagnostic Histopathol.*, May 2018.
- [5] **“Mucocutaneous diseases of the oral cavity,”** *Diagnostic Histopathol.*, May 2018.

- [1] **“Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study,”** *J. Clin. Oncol.*, Sep. 2011.
- [2] **“American Society of Clinical Oncology Provisional Clinical Opinion: The Integration of Palliative Care Into Standard Oncology Care,”** *J. Clin. Oncol.*, Mar. 2012.
- [3] **“Cost Sharing and Adherence to Tyrosine Kinase Inhibitors for Patients With Chronic Myeloid Leukemia,”** *J. Clin. Oncol.*, Feb. 2014.
- [4] **“Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update,”** *J. Clin. Oncol.*, Jan. 2017.
- [5] **“American Society of Clinical Oncology Statement: A Conceptual Framework to Assess the Value of Cancer Treatment Options,”** *J. Clin. Oncol.*, Aug. 2015.
- [6] **“Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline,”** *J. Clin. Oncol.*, Feb. 2018.
- [7] **“Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update,”** *J. Clin. Oncol.*, Oct. 2017.
- [8] **“MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2–Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy,”** *J. Clin. Oncol.*, Sep. 2017.
- [9] **“Minimal Residual Disease Assessed by Multiparameter Flow Cytometry in Multiple Myeloma: Impact on Outcome in the Medical Research Council Myeloma IX Study,”** *J. Clin. Oncol.*, Jul. 2013.
- [10] **“Alcohol and Cancer: A Statement of the American Society of Clinical Oncology,”** *J. Clin. Oncol.*, Jan. 2018.
- [11] **“Targeting Androgen Receptor and DNA Repair in Metastatic Castration-Resistant Prostate Cancer: Results From NCI 9012,”** *J. Clin. Oncol.*, Apr. 2018.
- [12] **“Chronic Myelogenous Leukemia: Pregnancy in the Era of Stopping Tyrosine Kinase Inhibitor Therapy,”** *J. Clin. Oncol.*, Apr. 2018.
- [13] **“Quality of Life From Canadian Cancer Trials Group MA.17R: A Randomized Trial of Extending Adjuvant Letrozole to 10 Years,”** *J. Clin. Oncol.*, Feb. 2018.
- [14] **“Breast Cancer Family History and Contralateral Breast Cancer Risk in Young Women: An Update From the Women’s Environmental Cancer and Radiation Epidemiology Study,”** *J. Clin. Oncol.*, May 2018.
- [15] **“Optimizing Anticancer Therapy in Metastatic Non-Castrate Prostate Cancer: American Society of Clinical Oncology Clinical Practice Guideline,”** *J. Clin. Oncol.*, May 2018.
- [16] **“Cumulative Burden of Morbidity Among Testicular Cancer Survivors After Standard Cisplatin-Based Chemotherapy: A Multi-Institutional Study,”** *J. Clin. Oncol.*, May 2018.
- [17] **“Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921,”** *J. Clin. Oncol.*, May 2018.

- [18] **“Three Versus 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Patients With Stage III Colon Cancer: Disease-Free Survival Results From a Randomized, Open-Label, International Duration Evaluation of Adjuvant (IDEA) France, Phase III Trial,”** *J. Clin. Oncol.*, May 2018.
- [19] **“Measurable Residual Disease at Induction Redefines Partial Response in Acute Myeloid Leukemia and Stratifies Outcomes in Patients at Standard Risk Without *NPM1* Mutations,”** *J. Clin. Oncol.*, May 2018.
- [20] **“FOLFOX or CAPOX in Stage II to III Colon Cancer: Efficacy Results of the Italian Three or Six Colon Adjuvant Trial,”** *J. Clin. Oncol.*, May 2018.
- [21] **“Curing More Prostate Cancer: Thinking Through the Options,”** *J. Clin. Oncol.*, May 2018.
- [22] **“Minimal Residual Disease Testing After Induction Chemotherapy for Acute Myeloid Leukemia: Moving Beyond Prognostication?,”** *J. Clin. Oncol.*, May 2018.
- [23] **“Advances in Adjuvant Therapy for Colon Cancer: *P* value or Practical**

## JAMA Oncology

- [1] **“My Unfortunate Introduction Into the Financial Toxicity of Cancer Care in America—March Forth,”** *JAMA Oncol.*, May 2018.
- [2] **“Lymphedema,”** *JAMA Oncol.*, May 2018.
- [3] **“Hepatocellular Carcinoma With Portal Venous Invasion,”** *JAMA Oncol.*, May 2018.
- [4] **“Insights Into the Management of Lymph Node–Positive Penile Cancer,”** *JAMA Oncol.*, May 2018.
- [5] **“*JAMA Oncology* —The Year in Review, 2017,”** *JAMA Oncol.*, May 2018.
- [6] **“Improved JAK Inhibition in Myelofibrosis—The Long Road Ahead,”** *JAMA Oncol.*, May 2018.
- [7] **“The Value of Behavioral Counseling for Skin Cancer Prevention,”** *JAMA Oncol.*, May 2018.
- [8] **“Using the Cancer Moonshot to Conquer Cancer Disparities,”** *JAMA Oncol.*, May 2018.
- [9] **“Mantle Cell Lymphoma—Time to Dismantle the Treatment Paradox,”** *JAMA Oncol.*, May 2018.
- [10] **“The US Food and Drug Administration’s Approval of Adjuvant Sunitinib for Renal Cell Cancer,”** *JAMA Oncol.*, May 2018.
- [11] **“Pediatric-Inspired Treatment Regimens for Adolescents and Young Adults With Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia,”** *JAMA Oncol.*, May 2018.
- [12] **“A Peculiar Adenocarcinoma,”** *JAMA Oncol.*, May 2018.
- [13] **“Association of High Body Mass Index and Hepatocellular Carcinoma in Patients With Chronic Hepatitis B Virus Infection,”** *JAMA Oncol.*, May 2018.
- [14] **“Concomitant Genetic Alterations With Response to Treatment and Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With *EGFR* -Mutant Advanced Non–Small Cell Lung Cancer,”** *JAMA Oncol.*, May 2018.

- [15] **“Association Between Circulating Tumor DNA and Pseudoprogression in Patients With Metastatic Melanoma Treated With Anti–Programmed Cell Death 1 Antibodies,”** *JAMA Oncol.*, May 2018.
- [16] **“‘Job Lock’ Among Long-term Survivors of Childhood Cancer,”** *JAMA Oncol.*, May 2018.
- [17] **“Comparison Between Adjuvant and Early-Salvage Postprostatectomy Radiotherapy for Prostate Cancer With Adverse Pathological Features,”** *JAMA Oncol.*, May 2018.
- [18] **“Seizure Rates in Enzalutamide-Treated Men With Metastatic Castration-Resistant Prostate Cancer and Risk of Seizure,”** *JAMA Oncol.*, May 2018.
- [19] **“Safety and Efficacy of Pembrolizumab Monotherapy in Patients With Previously Treated Advanced Gastric and Gastroesophageal Junction Cancer,”** *JAMA Oncol.*, May 2018.
- [20] **“Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia,”** *JAMA Oncol.*, May 2018.
- [21] **“Radiographic Progression-Free Survival as a Clinically Meaningful End Point in Metastatic Castration-Resistant Prostate Cancer,”** *JAMA Oncol.*, May 2018.
- [22] **“Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion,”** *JAMA Oncol.*, May 2018.
- [23] **“A Magnetic Resonance Imaging–Based Prediction Model for Prostate Biopsy Risk Stratification,”** *JAMA Oncol.*, May 2018.
- [24] **“Pacritinib vs Best Available Therapy, Including Ruxolitinib, in Patients With Myelofibrosis,”** *JAMA Oncol.*, May 2018.
- [25] **“Association of Sulindac and Erlotinib vs Placebo With Colorectal Neoplasia in Familial Adenomatous Polyposis,”** *JAMA Oncol.*, May 2018.
- [26] **“Prevalence of Cognitive Impairment and Association With Survival Among Older Patients With Hematologic Cancers,”** *JAMA Oncol.*, May 2018.
- [27] **“Treatment Trends and Outcomes for Patients With Lymph Node–Positive Cancer of the Penis,”** *JAMA Oncol.*, May 2018.

- [1] **“Reply to the letter to the editor ‘ESMO-MCBS v1.1: statistical and patient relevant shortcomings’ by Emprechtinger et al.,”** *Ann. Oncol.*, May 2018.
- [2] **“Nivolumab combined with ruxolitinib: antagonism or synergy?,”** *Ann. Oncol.*, May 2018.
- [3] **“Should de-escalation of bone-targeting agents be standard of care?,”** *Ann. Oncol.*, May 2018.
- [4] **“Effect of pembrolizumab on patients harboring uncommon epidermal growth factor receptor mutations,”** *Ann. Oncol.*, May 2018.
- [5] **“Eribulin in BRAF V600E-mutant metastatic colorectal cancer: case series and potential rationale,”** *Ann. Oncol.*, May 2018.
- [7] **“Combined immunotherapy encompassing intratumoral poly-ICLC, dendritic-cell vaccination and radiotherapy in advanced cancer patients,”** *Ann. Oncol.*, May 2018.
- [8] **“Restoration of conformation of mutant p53,”** *Ann. Oncol.*, May 2018.
- [9] **“Phase I study of the checkpoint kinase 1 inhibitor GDC-0575 in combination with gemcitabine in patients with refractory solid tumors,”** *Ann. Oncol.*, May 2018.
- [10] **“Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer,”** *Ann. Oncol.*, May 2018.
- [11] **“MSR1 repeats modulate gene expression and affect risk of breast and prostate cancer,”** *Ann. Oncol.*, May 2018.
- [12] **“Genetic profiling using plasma-derived cell-free DNA in therapy-naïve hepatocellular carcinoma patients: a pilot study,”** *Ann. Oncol.*, May 2018.
- [13] **“Combined pathologic-genomic algorithm for early-stage breast cancer improves cost-effective use of the 21-gene recurrence score assay,”** *Ann. Oncol.*, May 2018.
- [14] **“Evaluation of the eighth TNM classification on p16-positive oropharyngeal squamous cell carcinomas in the Netherlands and the importance of additional HPV DNA testing,”** *Ann. Oncol.*, May 2018.
- [15] **“Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma,”** *Ann. Oncol.*, Feb. 2018.
- [16] **“Adding abiraterone or docetaxel to long-term hormone therapy for prostate cancer: directly randomised data from the STAMPEDE multi-arm, multi-stage platform protocol,”** *Ann. Oncol.*, May 2018.
- [17] **“Malignant pleural mesothelioma immune microenvironment and checkpoint expression: correlation with clinical–pathological features and intratumor heterogeneity over time,”** *Ann. Oncol.*, May 2018.



- [19] **“CMS-dependent prognostic impact of KRAS and BRAFV600E mutations in primary colorectal cancer,”** *Ann. Oncol.*, May 2018.
- [20] **“RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer,”** *Ann. Oncol.*, May 2018.
- [21] **“RAS mutation analysis in circulating tumor DNA from patients with metastatic colorectal cancer: the AGEO RASANC prospective multicenter study,”** *Ann. Oncol.*, May 2018.
- [22] **“Efficacy and safety findings from DREAM: a phase III study of DHP107 (oral paclitaxel) versus IV paclitaxel in patients with advanced gastric cancer after failure of first-line chemotherapy,”** *Ann. Oncol.*, Feb. 2018.
- [23] **“Randomised phase III trial of vinflunine plus capecitabine versus capecitabine alone in patients with advanced breast cancer previously treated with an anthracycline and resistant to taxane,”** *Ann. Oncol.*, May 2018.
- [24] **“Final validation of the ProMisE molecular classifier for endometrial carcinoma in a large population-based case series,”** *Ann. Oncol.*, May 2018.
- [26] **“Physical activity in relation to risk of prostate cancer: a systematic review and meta-analysis,”** *Ann. Oncol.*, May 2018.
- [27] **“Systematic review and meta-analysis of the evidence for oral nutritional intervention on nutritional and clinical outcomes during chemo(radio)therapy: current evidence and guidance for design of future trials,”** *Ann. Oncol.*, May 2018.
- [28] **“Induction chemotherapy in locally advanced squamous cell carcinoma of the head and neck: role, controversy, and future directions,”** *Ann. Oncol.*, May 2018.
- [29] **“Methodology of clinical trials evaluating the incorporation of new drugs in the first-line treatment of patients with diffuse large B-cell lymphoma (DLBCL): a critical review,”** *Ann. Oncol.*, May 2018.
- [30] **“Targeting the human epidermal growth factor receptor 2 (HER2) oncogene in colorectal cancer,”** *Ann. Oncol.*, May 2018.
- [31] **“The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?,”** *Ann. Oncol.*, May 2018.
- [32] **“Should decisions on adding adjuvant chemotherapy in early-stage ER-positive breast cancer be based on gene expression testing or clinicopathologic factors or both?,”** *Ann. Oncol.*, May 2018.
- [33] **“Circulating tumor DNA detection in hepatocellular carcinoma,”** *Ann. Oncol.*, May 2018.
- [36] **“Antibody therapy targeting CD19 for B-cell non-Hodgkin’s lymphoma,”** *Ann. Oncol.*, May 2018.
- [37] **“Molecular risk stratification to direct therapy in endometrial cancer: ready for the clinic?,”** *Ann. Oncol.*, May 2018.
- [38] **“Detection of somatic RAS mutations in circulating tumor DNA from metastatic colorectal cancer patients: are we ready for clinical use?,”** *Ann. Oncol.*, May 2018.
- [39] **“HPV status, like politics, is local—evaluating p16 staining and a new staging system in a Dutch cohort of oropharynx cancer,”** *Ann. Oncol.*, May 2018.
- [40] **“The case for ‘successfully’ treating hormone naïve metastatic prostate cancer,”** *Ann. Oncol.*, May 2018.



Leading the way in experimental and clinical research in hematology

- [1] **“Extramedullary relapse of *KMT2A (MLL)*-rearranged acute lymphoblastic leukemia with lineage switch following blinatumomab,”** *Blood*, May 2018.
- [2] **“Detection of clonal hematopoiesis of indeterminate potential in clinical sequencing of solid tumor specimens,”** *Blood*, May 2018.
- [3] **“Paroxysmal cold hemoglobinuria with acute renal failure,”** *Blood*, May 2018.
- [4] **“MGUS, lymphoplasmacytic malignancies, and Gaucher disease: the significance of the clinical association,”** *Blood*, May 2018.
- [5] **“Pervasive mutations of JAK-STAT pathway genes in classical Hodgkin lymphoma,”** *Blood*, May 2018.
- [6] **“Preclinical evaluation of *NUDT15*-guided thiopurine therapy and its effects on toxicity and antileukemic efficacy,”** *Blood*, May 2018.
- [7] **“RNA-based *FLT3*-ITD allelic ratio is associated with outcome and ex vivo response to *FLT3* inhibitors in pediatric AML,”** *Blood*, May 2018.
- [8] **“Liquid biopsy for Hodgkin: a game changer?,”** *Blood*, May 2018.
- [9] **“Circulating tumor DNA reveals genetics, clonal evolution, and residual disease in classical Hodgkin lymphoma,”** *Blood*, May 2018.
- [10] **“Thromboembolism in acute lymphoblastic leukemia: results of NOPHO ALL2008 protocol treatment in patients aged 1 to 45 years,”** *Blood*, May 2018.
- [11] **“Exome chip analyses identify genes affecting mortality after HLA-matched unrelated-donor blood and marrow transplantation,”** *Blood*, May 2018.
- [12] **“The role of JAK2 inhibitors in MPNs 7 years after approval,”** *Blood*, May 2018.
- [13] **“Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study,”** *Blood*, May 2018.
- [14] **“14-3-3 proteins in platelet biology and glycoprotein Ib-IX signaling,”** *Blood*, May 2018.

# EUROPEAN UROLOGY

- [1] **“How Should a Man with Prostate Cancer Choose his Surgeon?”** *Eur. Urol.*, Jun. 2018.
- [2] **“Substitution Urethroplasty with Closure Versus Nonclosure of the Buccal Mucosa Graft Harvest Site: A Randomized Controlled Trial with a Detailed Analysis of Oral Pain and Morbidity,”** *Eur. Urol.*, Jun. 2018.
- [3] **“Answering Questions and Questioning Answers: More Evidence To Guide Decision-making About Chemohormonal Therapy in Metastatic Prostate Cancer,”** *Eur. Urol.*, Jun. 2018.
- [4] **“Oral Pain and Morbidity with Buccal Mucosa Grafts for Substitution Urethroplasty: Closure or Not,”** *Eur. Urol.*, Jun. 2018.
- [5] **“Survival Outcomes of Men with Lymph Node-positive Prostate Cancer After Radical Prostatectomy: A Comparative Analysis of Different Postoperative Management Strategies,”** *Eur. Urol.*, Jun. 2018.
- [6] **“Adjuvant Chemotherapy for Prostate Cancer: The Long and Winding Road,”** *Eur. Urol.*, Jun. 2018.
- [7] **“Re: Abiraterone for Prostate Cancer Not Previously Treated with Hormone Therapy,”** *Eur. Urol.*, Jun. 2018.
- [8] **“Burden of Metastatic Castrate Naive Prostate Cancer Patients, to Identify Men More Likely to Benefit from Early Docetaxel: Further Analyses of CHARTED and GETUG-AFU15 Studies,”** *Eur. Urol.*, Jun. 2018.
- [9] **“The Risks of Theft and Copyright Breach from Camera Use During Scientific Presentations: It’s Time for a Debate,”** *Eur. Urol.*, Jun. 2018.
- [10] **“Complex Polygenic Nature of Testicular Germ Cell Cancer Suggests Multifactorial Aetiology,”** *Eur. Urol.*, Jun. 2018.
- [11] **“Multiparametric Magnetic Resonance Imaging for Prostate-specific Antigen Recurrence After Radical Prostatectomy: Are We Leaving the ‘One Treatment Fits All Approach’ and Moving Towards Personalized Imaging-guided Treatment?,”** *Eur. Urol.*, Jun. 2018.
- [12] **“Robotic Intracorporeal Padua Ileal Bladder: Surgical Technique, Perioperative, Oncologic and Functional Outcomes,”** *Eur. Urol.*, Jun. 2018.
- [13] **“Two-years Postradiotherapy Biopsies: Lessons from MRC RT01 Trial,”** *Eur. Urol.*, Jun. 2018.
- [14] **“Comparison of Abiraterone Acetate and Docetaxel with Androgen Deprivation Therapy in High-risk and Metastatic Hormone-naïve Prostate Cancer: A Systematic Review and Network Meta-analysis,”** *Eur. Urol.*, Jun. 2018.
- [15] **“Re: A Novel Tool for Predicting Extracapsular Extension During Graded Partial Nerve Spraying in Radical Prostatectomy,”** *Eur. Urol.*, Jun. 2018.
- [16] **“Determinants of Patient Mobility for Prostate Cancer Surgery: A Population-based Study of Choice and Competition,”** *Eur. Urol.*, Jun. 2018.

- [17] **“Multiparametric Magnetic Resonance Imaging Is an Independent Predictor of Salvage Radiotherapy Outcomes After Radical Prostatectomy,”** *Eur. Urol.*, Jun. 2018.
- [18] **“Docetaxel Versus Surveillance After Radical Prostatectomy for High-risk Prostate Cancer: Results from the Prospective Randomised, Open-label Phase 3 Scandinavian Prostate Cancer Group 12 Trial,”** *Eur. Urol.*, Jun. 2018.
- [19] **“Repeat Transurethral Resection in Non–muscle-invasive Bladder Cancer: A Systematic Review,”** *Eur. Urol.*, Jun. 2018.
- [20] **“Re: Management of the Urologic Sepsis Syndrome,”** *Eur. Urol.*, Jun. 2018.
- [21] **“Non–risk-adapted Surveillance for Stage I Testicular Cancer: Critical Review and Summary,”** *Eur. Urol.*, Jun. 2018.
- [22] **“Nodal Metastases at Radical Prostatectomy: More Aggressive Disease Warrants Consideration of Multimodal Treatment,”** *Eur. Urol.*, Jun. 2018.
- [23] **“Re: Repair of Damaged Ligaments with Tissue Fixation System Minisling Is Sufficient to Cure Major Prolapse in All Three Compartments: 5-yr Data,”** *Eur. Urol.*, Jun. 2018.
- [24] **“Active Surveillance for Stage I Testicular Cancer: A Four-decade–old Experiment Proven Correct,”** *Eur. Urol.*, Jun. 2018.
- [25] **“Large-scale Sequencing of Testicular Germ Cell Tumour (TGCT) Cases Excludes Major TGCT Predisposition Gene,”** *Eur. Urol.*, Jun. 2018.
- [26] **“Active Surveillance Offers Functional Advantages Without Impacting Survival for Low-risk Prostate Cancer,”** *Eur. Urol.*, Jun. 2018.
- [27] **“Re: Jochen Walz. The ‘PROMIS’ of Magnetic Resonance Imaging Cost Effectiveness in Prostate Cancer Diagnosis? Eur Urol 2018;73:31–2,”** *Eur. Urol.*, Jun. 2018.
- [28] **“Long-term Psychological and Quality-of-life Effects of Active Surveillance and Watchful Waiting After Diagnosis of Low-risk Localised Prostate Cancer,”** *Eur. Urol.*, Jun. 2018.
- [29] **“Re: Duration of Urethral Catheterization After Urethroplasty: How Long Is Enough?,”** *Eur. Urol.*, Jun. 2018.
- [30] **“Re: A Randomized Study of Intraoperative Autologous Retropubic Urethral Sling on Urinary Control After Robotic Assisted Radical Prostatectomy,”** *Eur. Urol.*, Jun. 2018.
- [31] **“Patient-derived Hormone-naïve Prostate Cancer Xenograft Models Reveal Growth Factor Receptor Bound Protein 10 as an Androgen Receptor-repressed Gene Driving the Development of Castration-resistant Prostate Cancer,”** *Eur. Urol.*, Jun. 2018.
- [32] **“Abiraterone or Docetaxel Plus Androgen Deprivation in Hormone-Sensitive Prostate Cancer: More Questions Than Answers,”** *Eur. Urol.*, Jun. 2018.
- [33] **“Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening,”** *Eur. Urol.*, Jun. 2018.
- [34] **“Twenty-year Risk of Prostate Cancer Death by Midlife Prostate-specific Antigen and a Panel of Four Kallikrein Markers in a Large Population-based Cohort of Healthy Men,”** *Eur. Urol.*, Jun. 2018.
- [35] **“Expression of Androgen Receptor Splice Variant 7 or 9 in Whole Blood Does Not Predict Response to Androgen-Axis–targeting Agents in Metastatic Castration-resistant Prostate Cancer,”** *Eur. Urol.*, Jun. 2018.

# Gastroenterology



- [1] **“Less Is More: A Minimalist Approach to Endoscopy,”** *Gastroenterology*, May 2018.
- [2] **“New Developments in Managing Variceal Bleeding,”** *Gastroenterology*, May 2018.
- [3] **“Endoscopic Management of Pancreatobiliary Neoplasms,”** *Gastroenterology*, May 2018.
- [4] **“Advances and Challenges in Endoscopic Training,”** *Gastroenterology*, May 2018.
- [5] **“Advances in CRC Prevention: Screening and Surveillance,”** *Gastroenterology*, May 2018.
- [6] **“Endoscopic Management of Transmural Defects, Including Leaks, Perforations, and Fistulae,”** *Gastroenterology*, May 2018.
- [7] **“Endoscopic Full Thickness Resection,”** *Gastroenterology*, May 2018.
- [8] **“EUS-Guided Transluminal Interventions,”** *Gastroenterology*, May 2018.
- [9] **“Endoscopic Myotomy for Foregut Motility Disorders,”** *Gastroenterology*, May 2018.
- [10] **“Endoscopic Submucosal Dissection: Indications and Application in Western Endoscopy Practice,”** *Gastroenterology*, May 2018.
- [11] **“Novel Developments in Endoscopic Mucosal Imaging,”** *Gastroenterology*, May 2018.
- [12] **“Controversies in Endoscopic Eradication Therapy for Barrett’s Esophagus,”** *Gastroenterology*, May 2018.
- [13] **“Advances in Endoscopic Therapy,”** *Gastroenterology*, May 2018.



# The NEW ENGLAND JOURNAL of MEDICINE

- [1] “HIV-Associated Cancers and Related Diseases,” *N. Engl. J. Med.*, May 2018.
- [2] “Venetoclax–Rituximab in Chronic Lymphocytic Leukemia,” *N. Engl. J. Med.*, May 2018.
- [3] “A Pragmatic Trial of E-Cigarettes, Incentives, and Drugs for Smoking Cessation,” *N. Engl. J. Med.*, May 2018.
- [4] “A New Standard of Care for Advanced Lung Cancer,” *N. Engl. J. Med.*, May 2018.
- [5] “Preserving Access for People with Disabilities,” *N. Engl. J. Med.*, May 2018.
- [6] “ICU Admissions for Sepsis or Pneumonia in Australia and New Zealand in 2017,” *N. Engl. J. Med.*, May 2018.
- [7] “Pembrolizumab plus Chemotherapy in Metastatic Non–Small-Cell Lung Cancer,” *N. Engl. J. Med.*, May 2018.
- [8] “Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden,” *N. Engl. J. Med.*, May 2018.
- [9] “Digital Rectal Examination and Anoscopy,” *N. Engl. J. Med.*, May 2018.
- [10] “Fecal Microbiota Transplantation for Primary *Clostridium difficile* Infection,” *N. Engl. J. Med.*, Jun. 2018.
- [11] “Pemberton’s Sign in a Patient with a Goiter,” *N. Engl. J. Med.*, May 2018.
- [12] “Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström’s Macroglobulinemia,” *N. Engl. J. Med.*, Jun. 2018.
- [13] “Case 17-2018: A 40-Year-Old Woman with Leg Swelling and Abdominal Distention and Pain,” *N. Engl. J. Med.*, May 2018.